News WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Market Closed - Canadian Securities Exchange Other stock markets 09:49:31 2022-06-28 am EDT			5-day change	1st Jan Change
0.045 ^CAD	-.--%		-.--%	-.--%

Feb. 05	WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
Feb. 02	WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Feb. 05	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	Feb. 02	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	Jan. 30	CI
WPD Pharmaceuticals : Sp. z o. o., received the second tranche of the funds	Nov. 02	PU
WPD Pharmaceuticals : Sp. z o. o., received the first tranche of the funds	23-09-08	PU
WPD Pharmaceuticals : Polish Subsidiary Signs Investment Agreement with ACRX Investments Limited	23-09-01	PU
WPD Pharmaceuticals : Announces Closing of Convertible Debenture Private Placement	23-06-16	PU
WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in funding	23-06-14	CI
WPD Pharmaceuticals Inc. Provides Update on Research Project Pipeline	23-05-01	CI
WPD Pharmaceuticals Inc. Announces Directorate Appointments	23-05-01	CI
WPD Pharmaceuticals Inc. announced that it expects to receive CAD 0.3 million in funding	23-04-30	CI
WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy	23-01-17	CI
WPD Pharmaceuticals Announces First Two Sites Initiated in Poland in Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)	22-12-18	CI
WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin	22-12-05	CI
Liam Corcoran Resigns from WPD Pharmaceuticals Inc.'s Board of Directors, Effective December 1, 2022	22-11-24	CI
WPD Pharmaceuticals : Provides a Corporate Update	22-11-18	PU
WPD Pharmaceuticals Inc. announced that it expects to receive PLN 1.7 million in funding	22-09-13	CI
IIROC Trading Halt - WBIO	22-07-11	AQ
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	22-05-16	GL
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	22-05-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Summary

Filters